TCM Biotech International Corp.

Chairman: Shining Hsu
Date of Establishment: 1998/02/20
Tel: 886-2-2697-2628
Fax: 886-2-2697-2627
Address: 24F.-8, No.97, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City 221, Taiwan (U-TOWN B)


Company Profile:

TCM Biotech is a leading biotech company in Taiwan specializing in development of botanical new drugs for prevention and treatment of liver disease. TCM-700C HCV adjuvant agent uses Cordyceps sinensis mycelium as its main ingredient, and the phase II human clinical trial has been completed and approved by TFDA and USFDA. Recently, the phase III IND for TCM-700C has also been approved by TFDA on December, 2013. The preclinical development and clinical trials of TCM-700C have got the grants and awards from government. It shows the R&D capability and technology of TCM Biotech have been recognized by government. This development of botanical new drug TCM-700C has also been ratified as one of the primary index projects for drug development under cross-strait system in 2012, and TCM Biotech was the only remarkable representative in all companies developing in botanical new drug in Taiwan. Moreover, TCM Biotech was evaluated as one of the companies with the most international competition by Institute for Biotechnology and Medicine Industry in 2013. TCM Biotech has signed the technology licensing agreement of TCM-700C with China partner to conduct the phase III multi-center clinical trial together.

In addition, TCM Biotech also continues to develop the botanical new drugs in other liver disease, such as non-alcoholic fatty liver disease(NAFLD), HBV and liver fibrosis. The new drugs in treatment of NAFLD, HBV and HCV have all obtained the US patents.

The feature of TCM Biotech’s new drug development is focusing on the development of innovative technology and product for the prevention and treatment on liver disease. TCM Biotech combines the domestic and foreign experts in the study field of liver disease to conduct the development of new drugs on liver disease, sets the China and Taiwan as the first listing markets and then further develops the international market. Looking ahead, TCM Biotech will become an international biotech company specializing on development of new drug in prevention and treatment of liver disease.

R&D New Drug:

Project Code



Current Phase



Enhance the efficacy of HCV standard therapy by regulating the balance of Th1/Th2

Phase III Initiation



Converse the HBV surface antigen into negative by immunomodulatory.

Phase II Initiation


Nonalcoholic Fatty Liver Disease (NAFLD)

Treat the NAFLD by improving the damage caused from two-hit effect

Human Clinical Pilot Study/ IND preparation


Liver Fibrosis

Improve the liver fibrosis condition by decreasing TNF-α and IL-8 formed from inflammation

Pre-clinical Study